Once weekly insulin efsitora alfa reduces HbA1c by a similar amount to daily insulin degludec in people with type 2 diabetes, results of the QWINT-2 trial show.
Growing evidence suggests gestational diabetes increases the future risk of type 2 diabetes and cardiovascular disease, but when is the peak time for concern and are there racial and ethnic disparities?
Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.
Genetic testing was needed to diagnose mitochondrial disorder MIDD in a woman with diabetes, weight loss and poor glycemic control. Glycated hemoglobin and pancreatic function improved after treatment with a DPP-4 inhibitor.
Many patients are yet to benefit from the advances and approaches now at our disposal for the management of type 2 diabetes. How can the gaps and delays be addressed?
Our tailored content service will keep you up to date…
Receive newsletters curated for the busy specialist by our expert editorial team
Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.
With the growing importance of primary care in diabetes, this podcast discusses the evidence on continuous glucose monitoring (CGM) use, the role of primary healthcare, and practical tips for interpreting the ambulatory glucose profile (AGP) report.
Genetic testing was needed to diagnose mitochondrial disorder MIDD in a woman with diabetes, weight loss and poor glycemic control. Glycated hemoglobin and pancreatic function improved after treatment with a DPP-4 inhibitor.
A rare case of fulminant type 1 diabetes induced by SJS/TEN, which had developed in a patient taking carbamazepine and phenytoin. Glucose monitoring should be considered for patients with SJS/TEN.
The GLP-1 receptor agonist dulaglutide was unintentionally used by a woman with type 2 diabetes until the third trimester of an unplanned and unrecognized pregnancy, but what was the outcome?
Neonatal diabetes mellitus is a rare disorder of glucose metabolism with onset within the first 6 months of life. The initial treatment is based on insulin infusion. The technologies for diabetes treatment can be very helpful, even if guidelines …
Gestational diabetes mellitus (GDM) and its impact on adverse pregnancy outcomes have garnered increasing recognition. Certain modifiable risk factors, such as advanced age, obesity, gestational weight gain, and insulin resistance, play a crucial …
Type 2 Diabetes (T2D) is a chronic disease with increasing incidence and prevalence and serious chronic complications, especially from cardiovascular system. However, other organs can be affected too. Several studies have associated T2D …
The International Diabetes Federation Atlas reveals that as of 2021, an estimated 537 million individuals are currently afflicted by diabetes mellitus (DM), with projections indicating an increase to 643 million by 2030 and 783 million by 2045.
Despite many recent advances in its management, type 1 diabetes remains a burden for those living with the condition.
Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.
Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills.
Stay up to date with the rapidly changing CGM landscape. Learn how to implement and integrate CGM into diabetes management to improve patient care and outcomes.
Expert guidance on the multidisciplinary approach to identifying and managing chronic kidney disease in patients with type 2 diabetes, plus patient scenarios to assist your decision-making and put the latest clinical guidelines into context.
This program is not available to users in the UK and US.
Diabetes mellitus (DM) refers to a group of metabolic disorders characterized by an increased concentration of glucose in the blood, and individuals living with diabetes have a higher risk of morbidity and mortality when compared with the general …
Tyrosine kinase inhibitors (TKIs) have emerged as effective options in the treatment of cancer due to the demonstrated altered activation of these receptors during the development of diverse tumors [ 1 ].
Type 2 diabetes mellitus (T2DM) is a group of metabolic disorders characterized by long-term high blood glucose, which is caused by defects in insulin secretion and/or action [ 1 ]. It has become the third most serious chronic non-communicable …
Children with type 1 diabetes mellitus are at increased risk of developing diabetic kidney disease (DKD). This may occur either due to acute kidney injury during diabetes onset that later progresses to chronic kidney disease or due to poor …
Once weekly insulin efsitora alfa reduces HbA1c by a similar amount to daily insulin degludec in people with type 2 diabetes, results of the QWINT-2 trial show.
Once weekly insulin efsitora alfa reduces HbA1c by a similar amount to daily insulin degludec in people with type 2 diabetes, results of the QWINT-2 trial show.
Many patients are yet to benefit from the advances and approaches now at our disposal for the management of type 2 diabetes. How can the gaps and delays be addressed?
Once weekly insulin efsitora alfa reduces HbA1c by a similar amount to daily insulin degludec in people with type 2 diabetes, results of the QWINT-2 trial show.
